NEW YORK, September 2, 2026, 15:15 EDT
- Pfizer gained 1.7% to $29.04, hitting a 52-week peak at $29.09.
- The price is roughly 10 times the midpoint of Pfizer’s 2026 adjusted EPS forecast.
- The reported share price gives it an annualized dividend yield of 5.9%.
Pfizer Inc. NYSE:PFE rose 1.7% to $29.04 on Wednesday. The stock hit a 52-week high of $29.09. Trading volume was 24.4 million shares as of 15:14:50 EDT Yahoo Finance.
Even at its high, Pfizer trades at about 10 times its projected 2026 adjusted earnings. This relatively low multiple reflects investor uncertainty. The market values the improved policy outlook, but is not factoring in rapid earnings growth.
Pfizer intraday price
As of . Source: Yahoo Finance. Delayed market data.
Nine additional small drugmakers joined the latest round of U.S. pricing agreements this week. Over 20 companies are now covered by such deals, according to a Reuters factbox. Pfizer’s initial framework continues to appear as a model for the sector.
In September, Pfizer accepted most-favored-nation conditions for Medicaid as well as new pharmaceuticals. The company’s direct channel typically provides savings averaging 50% on eligible medications. Discounts may go as high as 85%, but full financial details are confidential Pfizer agreement.
What Pfizer exchanged for pricing commitments
Publicly disclosed terms; confidential provisions are excluded.
Sources: Pfizer and its annual report.
Chief Executive Albert Bourla said the agreement delivers “certainty and stability” regarding tariffs and pricing. The tariff exemption remains in place for three years, contingent upon additional U.S. manufacturing investment.
This transparency helps a company still navigating fluctuating product demand. Second-quarter revenue increased by 3% to $15.03 billion. Pfizer maintained its adjusted EPS forecast at $2.80 to $3.00 and raised its revenue outlook to $60.5 billion-$62.5 billion quarterly results.
Pfizer’s Q2 product growth was sharply split
Year-over-year operational revenue change; bar length shows absolute change.
Quarter ended June 28, 2026. Source: Pfizer.
The non-COVID portfolio acts as a cushion. Newly launched and acquired products posted operational growth of 18%. Pfizer forecasts COVID-related product revenue of around $4 billion for 2026, a decrease from its earlier estimate of $5 billion.
With a midpoint adjusted EPS multiple of 10.0 at $29.04, Pfizer’s $0.43 dividend paid each quarter equates to a 5.9% yield on an annualized basis. The company has now maintained its quarterly dividend for 351 straight periods, as announced this week dividend release.
Shares of sector peers also moved higher. Johnson & Johnson NYSE:JNJ climbed 1.4%, with Merck & Co. NYSE:MRK up 1.1%. Eli Lilly and Company NYSE:LLY edged 0.3% higher, and AbbVie Inc. NYSE:ABBV was up 0.2%.
Large U.S. drugmakers moved higher
Session change at about 15:15 EDT; bar height is scaled to percentage gain.
As of September 2, 2026, about 15:15 EDT. Source: Yahoo Finance quote data for PFE, JNJ, MRK, LLY and ABBV.
Pfizer’s newsroom contained no company release for September as of reporting time. Wednesday’s movement likely reflects broader factors rather than a new product announcement. The 52-week high is more significant than the day’s news flow.
Risks: Confidentiality around pricing complicates revenue impact assessment. Additional products will become subject to Medicare negotiations starting in 2027. Delays in the pipeline, declining vaccine demand, or increased investment spending could further strain cash flow Pfizer annual report.
The upcoming regulatory milestone is scheduled for the fourth quarter. The U.S. Food and Drug Administration will rule on the broader use of Talzenna combined with Xtandi. The outcome will indicate if advances in the pipeline are enough to support the current valuation shift.
Related articles: NYSE:PFE
